No profile data available.
Tvardi Therapeutics, Inc. (TVRD) is a healthcare company in the urinary system treatment drugs industry, based in Sugar Land, United States, with about 12 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$18.21 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $13.74 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.
Tvardi Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$13.74 million as of October 9, 2026.
Listed companies of a similar size in the same industry (urinary system treatment drugs) include Jyong Biotech Ltd. (MENS), Unicycive Therapeutics, Inc. (UNCY), Cyclerion Therapeutics, Inc. (CYCN), Nymox Pharmaceutical Corporation (NYMXF).